Stem cell transplantation for sickle cell disease: Can we reduce the toxicity?

Pediatric Pathology and Molecular Medicine

Volumn 20, Issue 1, 2001, Pages 73-86

  Fixler, J ^a   Vichinsky, E ^a   Walters, M C ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Anemia; Bone marrow transplantation; Nonmyeloblative stem cell transplantation; Sickle cell; Transplantation chimera

Indexed keywords

ANTIOXIDANT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOLLITROPIN; HEMOGLOBIN F; HEMOGLOBIN S; LUTEINIZING HORMONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; TREATMENT INDICATION; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ANIMAL; BIOSYNTHESIS; BONE MARROW TRANSPLANTATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHILD; DOG; FEMALE; FORECASTING; HISTOCOMPATIBILITY; INFERTILITY; MALE; MULTICENTER STUDY; RISK; SEIZURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; ANIMAL; BONE MARROW TRANSPLANTATION; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHILD; DOGS; FEMALE; FETAL HEMOGLOBIN; FORECASTING; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFERTILITY; MALE; MULTICENTER STUDIES; RISK; SEIZURES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 85047684533     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/15513810109168818     Document Type: Review

References (62)

1. The intercellular polymerization of sickle hemoglobin and its relevance to sickle cell disease
2. Transfusion practice for patients with sickle cell disease
3. Drug therapy: Management of sickle cell disease
4. Sickle cell disease
5. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography
6. Safety of the blood supply in the United States: Opportunities and controversies
7. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies
8. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia
9. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease
10. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?
11. Hydroxyurea therapy in children severely affected with sickle cell disease
12. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial
13. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group
14. Bone-marrow transplantation in a patient with sickle-cell anemia
15. Bone marrow transplantation in five children with sickle cell anemia
16. Bone marrow transplantation in sickle cell anemia - The dillema of choice
17. Impact of bone marrow transplantation for symptomatic sickle cell disease: Long-term follow-up evaluations
18. Report of the French experience concerning 26 children transplanted for sever sickle cell disease
19. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium
20. Bone marrow transplantation for sickle cell disease
21. Prediction of adverse outcomes in children with sickle cell disease
22. Bone marrow transplantation for sickle cell disease: The United States experience
23. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
24. Mixed chimerism in thalassemic patients after bone marrow transplantation
25. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group
26. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: The impact of conditioning regimen without total-body irradiation - A report for the Societe Francaise de Greffe de Moelle
27. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone
28. Growth and development after hematopoietic cell transplantation
29. Neurologic complications after allogenic marrow transplantation for sickle cell anemia
30. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: Current results and future directions
31. Bone marrow transplantation corrects the splenic reticuloendothelial dysfunction in sickle cell anemia
32. Bone marrow transplantation in sickle-cell anemia in Pesaro
33. Neuropsychologic impairment in children with sickle cell anemia
34. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuro-psychology committee of the cooperative study of Sickle cell disease
35. Bone marrow transplantation in a young child with sickle cell anemia
36. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions
37. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: A case report with a four-year follow-up
38. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
39. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
40. Bone marrow transplantation for pediatric malignancies
41. Graft-versus-host disease
42. Transplanted sickle-cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity
43. Stable mixed chimerism after bone marrow transplantation (BMT) for sickle cell disease (SCD)
44. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloblative chemotherapy and HLA-mismatched bone marrow transplantation
45. Immunogenetic consequences of vascular anastomoses between bovine twins
46. Mixed chimerism as an approach for the induction of transplantation tolerance
47. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
48. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen
49. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers
50. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat: A relationship between allo- and autoimmunity
51. Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice
52. Repopulation of host lympho-hematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes
53. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation
54. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice
55. Protection against autoimmune diabetes in mixed bone marrow chimeras
56. A partial conditioning strategy for achieving mixed chimerism in the rat: Tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment
57. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum
58. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immuno-suppression after marrow transplantation
59. Coexistence of two functioning T-cell repertoires in healthy Ex-thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation
60. Analysis of chimerism in children with haemoglobinopathies undergoing stem cell transplantation
61. Analysis of β-Globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation